AU2020348295A1 - Anti-stem cell factor antibodies and methods of use thereof - Google Patents

Anti-stem cell factor antibodies and methods of use thereof Download PDF

Info

Publication number
AU2020348295A1
AU2020348295A1 AU2020348295A AU2020348295A AU2020348295A1 AU 2020348295 A1 AU2020348295 A1 AU 2020348295A1 AU 2020348295 A AU2020348295 A AU 2020348295A AU 2020348295 A AU2020348295 A AU 2020348295A AU 2020348295 A1 AU2020348295 A1 AU 2020348295A1
Authority
AU
Australia
Prior art keywords
antibody
fragment
seq
scf248
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020348295A
Other languages
English (en)
Inventor
Martin Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Inc
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of AU2020348295A1 publication Critical patent/AU2020348295A1/en
Assigned to INSMED INCORPORATED reassignment INSMED INCORPORATED Request for Assignment Assignors: Opsidio, LLC
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020348295A 2019-09-16 2020-09-16 Anti-stem cell factor antibodies and methods of use thereof Pending AU2020348295A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900927P 2019-09-16 2019-09-16
US62/900,927 2019-09-16
PCT/US2020/050973 WO2021055408A1 (en) 2019-09-16 2020-09-16 Anti-stem cell factor antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2020348295A1 true AU2020348295A1 (en) 2022-04-07

Family

ID=74868426

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020348295A Pending AU2020348295A1 (en) 2019-09-16 2020-09-16 Anti-stem cell factor antibodies and methods of use thereof
AU2020351138A Pending AU2020351138A1 (en) 2019-09-16 2020-09-16 Anti-stem cell factor antibodies and methods of use thereof in renal disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020351138A Pending AU2020351138A1 (en) 2019-09-16 2020-09-16 Anti-stem cell factor antibodies and methods of use thereof in renal disease

Country Status (28)

Country Link
US (5) US20220324957A1 (https=)
EP (3) EP4031569B1 (https=)
JP (4) JP7698635B2 (https=)
KR (1) KR20220079561A (https=)
CN (2) CN118561997A (https=)
AR (1) AR119979A1 (https=)
AU (2) AU2020348295A1 (https=)
BR (1) BR112022004776A2 (https=)
CA (2) CA3154649A1 (https=)
CL (1) CL2022000633A1 (https=)
CO (1) CO2022003661A2 (https=)
DK (1) DK4031569T3 (https=)
DO (1) DOP2022000058A (https=)
EC (1) ECSP22022676A (https=)
ES (1) ES3053942T3 (https=)
FI (1) FI4031569T3 (https=)
IL (1) IL291385A (https=)
MX (1) MX2022003159A (https=)
PE (1) PE20230090A1 (https=)
PH (1) PH12022550647A1 (https=)
PL (1) PL4031569T3 (https=)
PT (1) PT4031569T (https=)
SA (1) SA522431966B1 (https=)
TW (2) TWI875812B (https=)
UA (1) UA129546C2 (https=)
UY (1) UY38883A (https=)
WO (2) WO2021055408A1 (https=)
ZA (1) ZA202203272B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
AU2020348295A1 (en) * 2019-09-16 2022-04-07 Insmed Incorporated Anti-stem cell factor antibodies and methods of use thereof
KR20250167153A (ko) * 2023-03-03 2025-11-28 셀덱스 쎄라퓨틱스, 인크. 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물
WO2026079764A1 (ko) * 2024-10-10 2026-04-16 아주대학교산학협력단 마우스 scf를 중화하는 항체 및 이의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2657113B2 (ja) * 1989-10-16 1997-09-24 アムジエン・インコーポレーテツド 幹細胞因子
US7144731B2 (en) * 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5911988A (en) 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
JP3583214B2 (ja) 1995-12-01 2004-11-04 株式会社ニチレイ ヒトｓｃｆに対するモノクローナル抗体
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
PL1691837T3 (pl) 2003-12-10 2012-11-30 Squibb & Sons Llc IP-10 przeciwciała i ich zastosowanie
US7611707B2 (en) 2004-04-29 2009-11-03 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods thereof
WO2006002064A2 (en) 2004-06-14 2006-01-05 Aerovance, Inc. Antibody inhibiting stem cell factor activity and use for treatment of asthma
US20080248050A1 (en) 2006-06-30 2008-10-09 Uchicago Argonne, Llc Meta-specific vaccine, method for treating patients immunized with meta-specific vaccine
US20110189093A1 (en) 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
AU2012205718B2 (en) 2011-01-10 2017-07-06 The Regents Of The University Of Michigan Stem cell factor inhibitor
US20150018408A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
KR101384360B1 (ko) 2012-05-04 2014-04-14 아주대학교산학협력단 Ｓｃｆ 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
US10927153B1 (en) 2015-05-20 2021-02-23 University Of South Florida Synthetic plasmodium antigens, compositions, and uses thereof
KR102438650B1 (ko) * 2015-08-19 2022-08-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
KR20170022409A (ko) 2015-08-20 2017-03-02 주식회사 와이바이오로직스 Scf 특이적 항체
US11091559B2 (en) * 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
CA3009488A1 (en) 2015-12-22 2017-06-29 Abbvie Stemcentrx Llc Novel anti-upk1b antibodies and methods of use
PL3523421T3 (pl) 2016-10-05 2025-06-09 Cellresearch Corporation Pte. Ltd. Sposób izolowania mezenchymalnych komórek macierzystych z błony owodniowej pępowiny przy użyciu podłoża do hodowli komórkowej
WO2019066093A1 (ko) 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
WO2019088658A1 (ko) 2017-10-31 2019-05-09 주식회사 컴워스파마 Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
KR102131898B1 (ko) 2017-10-31 2020-07-08 주식회사 노벨티노빌리티 Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
CA3117098A1 (en) 2018-10-19 2020-04-23 The General Hospital Corporation Compositions and methods for treatment of liver disease
AU2020348295A1 (en) 2019-09-16 2022-04-07 Insmed Incorporated Anti-stem cell factor antibodies and methods of use thereof
US20240182556A1 (en) 2021-03-17 2024-06-06 Opsidio, LLC Stem cell factor antibodies and methods of use thereof

Also Published As

Publication number Publication date
US20220324957A1 (en) 2022-10-13
BR112022004776A2 (pt) 2022-06-21
EP4031176A4 (en) 2023-11-29
CL2022000633A1 (es) 2022-11-11
CA3154649A1 (en) 2021-03-25
FI4031569T3 (fi) 2025-11-14
AU2020351138A1 (en) 2022-03-31
EP4031176A1 (en) 2022-07-27
JP7717687B2 (ja) 2025-08-04
PT4031569T (pt) 2025-11-12
JP7698635B2 (ja) 2025-06-25
UY38883A (es) 2021-04-30
UA129546C2 (uk) 2025-05-28
US20230019680A1 (en) 2023-01-19
EP4031569B1 (en) 2025-08-20
EP4031569A4 (en) 2023-10-18
WO2021055408A1 (en) 2021-03-25
JP2025165991A (ja) 2025-11-05
IL291385A (en) 2022-05-01
CN114729036B (zh) 2024-07-02
WO2021055409A1 (en) 2021-03-25
US20210079084A1 (en) 2021-03-18
EP4650367A3 (en) 2026-03-04
ES3053942T3 (en) 2026-01-28
TW202523696A (zh) 2025-06-16
PL4031569T3 (pl) 2026-02-16
PH12022550647A1 (en) 2023-03-27
CA3154648A1 (en) 2021-03-25
US12410246B2 (en) 2025-09-09
JP2022547733A (ja) 2022-11-15
MX2022003159A (es) 2022-04-07
US11939373B2 (en) 2024-03-26
CN114729036A (zh) 2022-07-08
PE20230090A1 (es) 2023-01-16
TWI875812B (zh) 2025-03-11
EP4031569A1 (en) 2022-07-27
CO2022003661A2 (es) 2022-04-08
DOP2022000058A (es) 2022-08-31
ECSP22022676A (es) 2022-05-31
DK4031569T3 (da) 2025-11-17
JP2025125563A (ja) 2025-08-27
US20220340655A1 (en) 2022-10-27
TW202124434A (zh) 2021-07-01
SA522431966B1 (ar) 2025-05-18
AR119979A1 (es) 2022-01-26
ZA202203272B (en) 2022-12-21
CN118561997A (zh) 2024-08-30
JP2022548646A (ja) 2022-11-21
KR20220079561A (ko) 2022-06-13
US20240076367A1 (en) 2024-03-07
EP4650367A2 (en) 2025-11-19

Similar Documents

Publication Publication Date Title
US12410246B2 (en) Anti-stem cell factor antibodies and methods of blocking the interaction between SCF and c-Kit
IL229254A (en) Antibodies that bind c5ar and use them for treatment
WO2014089209A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
US20250250341A1 (en) Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
WO2015191934A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
JP2023528535A (ja) セリン４１３においてリン酸化されたタウを標的化する高親和性抗体
AU2022237556A9 (en) Stem cell factor antibodies and methods of use thereof
EP4428239A1 (en) Novel nav1.7 monoclonal antibody
RU2844744C1 (ru) Антитела против фактора стволовых клеток и способы их применения
HK40078116B (en) Anti-stem cell factor antibodies and methods of use thereof
HK40078116A (en) Anti-stem cell factor antibodies and methods of use thereof
HK40112825A (zh) 抗干细胞因子抗体及其使用方法
AU2024331270A1 (en) Anti-tslp antibody constructs and uses thereof
CN121399160A (zh) 靶向ccr2的抗体

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: INSMED INCORPORATED

Free format text: FORMER APPLICANT(S): OPSIDIO, LLC